Draft:Emmanuel Kamberov

Emmanuel Kamberov (born Feb 24, 1962) is a Bulgarian American scientist and inventor of technologies for Molecular Diagnostics, Genetic Screening, Reproductive Health, Infectious Diseases and Single Cell Genomics. He is the leading author of a patent invention that led to a $75 million exit (Rubicon Genomics, Inc. acquired by Takara Holdings in 2017 ) The invention, known as PicoPLEXundefined  was the first commercial technology to successfully and accurately amplify the whole genome of a single cell  for molecular genetic screening of copy number variants (CNV) in in vitro fertilization (IVF). Together with intracytoplasmic sperm injection (ICSI), it is often referred to as assisted reproductive technology (ART). Currently, PicoPLEXundefined (a.k.a. SurePLEXundefined, SingleSequndefined) is used by over 95 percent of all in vitro fertilization (IVF) clinics globally as the core chemistry of the two main commercial platforms: the Illumina, Inc. VeriSequndefined and the Thermo Fisher Scientific ReproSequndefined NGS for genetic screening by next generation sequencing (NGS). Since its adoption in 2010, PicoPLEXundefined (SurePLEXundefined) has significantly improved the accuracy of preimplantation genetic screening of human embryos for IVF, lowered the percent of babies born with genetic abnormalities and appreciably reduced the incidence of multiple births in IVF. The technology has contributed significantly to giving over eight million couples with infertility problems around the globe the chance of having healthy babies

Early life and education
Emmanuel Kamberov was born in Veliko Tarnovo, Bulgaria’s ancient capital city to father Stephan Kamberov, an Orthodox priest and mother Ivanka Kamberova. He grew up in Bansko, Bulgaria. In 1991, he graduated from the Plovdiv University "Paisii Hilendarski” with a Ph.D.degree in microbiology. He taught microbiology at the Department of Biochemistry and Microbiology of the Plovdiv University "Paisii Hilendarski” since early 1988. In 1992, he permanently relocated to the U.S. along with wife, Valentina Kamberov, and older son, Steven Kamberov.

Career
In 1992 Dr. Kamberov enrolled in a postdoctoral research fellowship at Wayne State University’s Department of Biochemistry. In 1993 he moved to the University of Michigan where he held postdoctoral research fellow positions at the Departments of Biological Chemistry, Internal Medicine Rheumatology, and Howard Hughes Medical Institute. He joined biotechnology startup company Rubicon Genomics, Inc. in 2001 as employee number one, where he progressed from a senior scientist to a vice president of research in about seven years. After the acquisition of Rubicon Genomics, Inc. by Takara Holdings in 2017, Kamberov was appointed as a senior director of research and development at Takara Bio U.S. where he remained until 2019. During the SARS-CoV2 pandemic, Kamberov led the research and development effort to successfully develop and clinically implement a number of rapid and sensitive molecular tests for Lynx Dx and Rapid Biosense, both high complexity CLIA-certified COVID testing laboratories in the state of Michigan. In late 2022, Kamberov joined Signal Bioscience, a startup developing new molecular diagnostic detection technologies. Kamberov is a member of the New York Academy of Sciences since 1996, a certified SCENAR pain therapist since 2013, and a DJ and producer of electronic music under the artist name DJ Emmo undefined since 2008.undefined

Bibliography, citations and patent inventions
https://scholar.google.com/citations?user=PnXSrYoAAAAJ&hl=en

https://scholar.google.com/citations?user=PnXSrYoAAAAJ&hl=en#d=gsc_md_hist&t=1707242343195

https://www.researchgate.net/profile/Emmanuel-Kamberov-3/3

https://www.sciencedirect.com/author/55398769300/emmanuel-s-kamberov

https://patents.justia.com/inventor/emmanuel-kamberov?page=2

Personal life
Emmanuel Kamberov lives with his wife Valentina Kamberov, a nurse at VA Hospital and younger son Benjamin Kamberov in Ann Arbor, Michigan.